

N.B. English translation is for convenience purposes only

The Board of Directors' report referred to in Chapter 13, Section 6 of the Swedish Companies Act

The Board of Directors of NeuroVive Pharmaceutical AB (publ), reg. no. 556595-6538, (the "Company") submits the following report as referred to in Chapter 13, Section 6 of the Swedish Companies Act.

After the submission of the annual report for the financial year 2018, which includes the latest adopted balance sheet and profit and loss account, no events of material significance for the Company's financial position have occurred, except from what is stated in the Company's Year End Report for the period 1 January 2019 to 31 December 2019, **Appendix 1**.

Place: Lund

Date: 19 February 2020

David Laskow-Pooley

David Beijker

Jan Törnell

Denise Goode

Magnus Persson